Empagliflozin Modestly Improves Liver Enzymes in MASLD, Not Lipids
This meta-analysis clarifies where empagliflozin does and does not help patients with metabolic dysfunction-associated steatotic liver disease, a question directly relevant to endocrinology and obesity pharmacists managing overlapping cardiometabolic disease.
Empagliflozin reduces liver enzymes in MASLD patients, showing promise.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is common, linked to obesity and dyslipidemia, and lacks effective treatment options. Empagliflozin significantly reduced liver enzymes alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT) and modestly reduced body mass index (BMI) but had no significant impact on lipid profiles. Empagliflozin may offer a modest benefit for liver enzyme reduction in MASLD, but the study's findings are limited by small sample sizes and short follow-up, requiring cautious interpretation. Empagliflozin shows potential benefits for liver enzyme reduction in MASLD but requires further research.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Authors:Karimi M, Tahmasebi A, Ramezanipour S, Rad FN, Valizadeh F, Abedi P, Gholami M, Sobhan Ardekani N, Pirshahid ME
Citation:Karimi M, Tahmasebi A, Ramezanipour S, et al. Efficacy of Empagliflozin on Liver Enzymes, Lipid Profile and BMI in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis. Endocrinology, diabetes & metabolism. 2026;9(4):e70294. doi:10.1002/edm2.70294
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.